FDA to review Amgen drug for use on melanoma
Amgen said on Wednesday that its Biologics License Application (BLA) for talimogene laherparepvec will be reviewed by the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) and the Cellular, Tissue and Gene Therapies Advisory Committee. Read More »